VEGF promotes the proliferation of bone marrow derived mesenchymal stem cells through ERK1/2 signal pathway.
- Author:
Xia KONG
1
;
Fei ZHENG
;
Ling-Yun GUO
;
Jian-Ye YANG
;
Lei ZHANG
;
Jun-Ming TANG
;
Yong-Zhang HUANG
;
Jia-Ning WANG
Author Information
1. Institute of Clinical Medicine, Department of Cardiology, Peolpe Hospital, Yunyang Medical College, Shiyan 442000, Hubei Province, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Marrow Cells;
cytology;
Cell Differentiation;
Cell Proliferation;
Cells, Cultured;
Extracellular Signal-Regulated MAP Kinases;
metabolism;
Flavonoids;
pharmacology;
Imidazoles;
pharmacology;
Mesenchymal Stromal Cells;
cytology;
Pyridines;
pharmacology;
Rats;
Rats, Sprague-Dawley;
Signal Transduction;
Vascular Endothelial Growth Factors;
pharmacology
- From:
Journal of Experimental Hematology
2010;18(5):1292-1296
- CountryChina
- Language:Chinese
-
Abstract:
In order to explore the effect of VEGF on mesenchymal stem cell (MSC) proliferation and its possible signal transduction mechanism, MSC culture was performed with the classical bone marrow adhering method; characteristics of passage 3 rat MSC (P3MSC) was identified through multi-differentiation and surface marker assay (CD34, CD45, CD90, CD29); P3MSC were treated with 20 ng/ml VEGF, and the effect of VEGF on the MSC proliferation was measured during 12, 36 and 72 hours by MTT assay. Subsequently, P3MSC were treated with extracellular-signal regulated kinase (ERK1/2) inhibitor PD98059 (50 µmol/L) or p38 mitogen-activated protein kinase (p38MAPK) inhibitor SB203580 (30 µmol/L) for 30 minutes, the culture medium was replaced with new medium including 20 ng/ml VEGF. After 72 hours, the effect of PD98059 or SB203580 on MSC proliferation mediated by VEGF was measured by MTT assay. The result showed that the cultured MSC expressed PDGFR-α, PDGFR-β and NRP1, but did not express VEGF-R (Flk1 and Flt1). The MSC had the multi-differentiation ability and displayed the characteristics of CD90+ (96.7%), CD29+ (94.6%), CD34- (0.79%) and CD45- (0.84%). The MSC proliferation rate increased gradually with prolonging of the functioning time of 20 ng/ml VEGF, and MSC proliferation rate may reach to maximum value after treating with 20 ng/ml VEGF for 72 hours. The effect of VEGF on MSC proliferation was found to be abolished, even was under level of control group after treating with PD98059 or SB203580 for 30 minutes. Furthermore, the inhibitory effect of PD98059 on MSC proliferation was obviously higher than that of SB203580. It is concluded that the VEGF can promote MSC proliferation, and its possible mechanism may relate to ERK1/2 pathway.
